WO2018005308A1 - Procédés de prognostic et de diagnostic de phytothérapie permettant de traiter les dermatoses, les maladies auto-immunes et les troubles inflammatoires - Google Patents

Procédés de prognostic et de diagnostic de phytothérapie permettant de traiter les dermatoses, les maladies auto-immunes et les troubles inflammatoires Download PDF

Info

Publication number
WO2018005308A1
WO2018005308A1 PCT/US2017/039177 US2017039177W WO2018005308A1 WO 2018005308 A1 WO2018005308 A1 WO 2018005308A1 US 2017039177 W US2017039177 W US 2017039177W WO 2018005308 A1 WO2018005308 A1 WO 2018005308A1
Authority
WO
WIPO (PCT)
Prior art keywords
huang
grams
sheng
levels
prognostic
Prior art date
Application number
PCT/US2017/039177
Other languages
English (en)
Inventor
Nadav Shraibom
Anu T. Singh
Manu Jaggi
Eran Steinberg
Ritu Verma
Alka MADAAN
Original Assignee
Sirbal Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/197,745 external-priority patent/US20170000837A1/en
Priority claimed from US15/197,740 external-priority patent/US20170000836A1/en
Application filed by Sirbal Ltd. filed Critical Sirbal Ltd.
Publication of WO2018005308A1 publication Critical patent/WO2018005308A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Definitions

  • diagnostic test kits configured to measure levels of certain panels of one or more diagnostic markers that are most indicative of a patient's disposition with a disease, condition or disorder, or combination or ailments.
  • prognostic test kits configured to measure levels of certain panels of one or more prognostic markers that are most indicative of a patient's tendency to respond safely and effectively to certain treatments or combinations of treatments for certain diseases, conditions or disorders.
  • Figure 6 schematically illustrates example steps on a tablet formulation process in accordance with certain embodiments.
  • Figure 8 illustrates a hair growth cycle and a hair fall control strategy in accordance with certain embodiments.
  • Figure 9 illustrates certain targets of combinations of Da Huang, Sheng Di Huang and Jin Yin Hua in accordance with certain embodiments.
  • Figure 10 illustrates certain putative mechanisms of combinations of Da Huang Sheng Di Huang and Jin Yin Hua in accordance with certain embodiments.
  • Figure 11 illustrates certain psoriasis target therapies for administration along with combinations of Da Huang Sheng Di Huang and Jin Yin Hua in accordance with certain embodiments.
  • a medicinal composition may be formulated as a shampoo and applied to the scalp.
  • the medicinal composition may be formulated as a shampoo, conditioner, cream, lotion, ointment or other topical scalp or hair treatment.
  • the medicinal composition may be formulated as a cream, lotion, ointment or other topical skin treatment.
  • Effective doses of the medicine may include 1.0wt.%-15.0wt.% of said herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • osteoarthritis seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, Crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Page
  • the medical kit may also include a prognostic kit including a prognostic test kit and a prognostic indicator.
  • the prognostic test kit may be configured for measuring a level or combination of levels of one or more inflammatory cytokines, growth factors; cytokine receptors; ligand to surface markers, chemokines, protoangiogenic mediators, automicrobial proteins, neuropeptides, oxidative stress markers, dendritic cells (DC), plasmacytoid DC, monocytes, macrophages, histamines, T&B lymphocytes, or theranostic biomarkers, or combinations thereof, in a second bodily fluid or skin sample, or both, after a prognostic period of treatment.
  • the prognostic indicator may be configured for providing a prognostic result for the patient based on a comparison of said measured level or combination of levels in the first and second bodily fluid or skin sample, or both.
  • Effective doses of the medicinal formulation may include 2.5wt.%-5.0wt.% of said herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • autoimmune inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, Crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma,
  • the medicinal composition may be formulated as a shampoo and applied to the scalp.
  • the method may further include administering, in combination with said medicinal composition that comprises effective doses between 20-160 mg/kg of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua, one or more additional medicines including an IL-12, IL-23, TNF alpha, JAK, STAT, IL-17, PDE4, p40 subunit of IL-12 and/or IL-23 and/or a humanized p40 monoclonal antibody, IL-22, IL-20, IL-23/pl9, JAK3, Thl, Thl7 and/or Th22 cell, IFN gamma, IL-17R, IL-19, sPLA2, NO (nitric oxide), VEGF, IL-24, kinase, tyrosine, topoisomerase, IL-1, IL-6, IL-8, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, MAPKl, BRAF, MEK1, PD-1,
  • the method includes measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-a, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-1- ⁇ , IL-l-RA, IL-8, IL-9, IL-10, IL-12, IL- 19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF- ⁇ , G-CSF, IFN- ⁇ , IP- 10, MIP-1, PDGF-RB, PDGF- BB, MIP-1- ⁇ , RANTES, VEGF, JAK, JAKl, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sap
  • Effective doses may include 1.0wt.%-15.0wt.% of said herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • the medicinal formulation includes shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection packet, IV fluid package, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, said medicinal formulation comprising a predetermined number of one or more effective doses, each effective dose including between 20-160 mg/kg of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • the medicinal formulation includes shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection packet, IV fluid package, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof.
  • the medicinal formulation includes a predetermined number of one or more effective doses, each effective dose including between 1.0wt.%-15wt.% of an herbal combination of Da Huang, Sheng di Huang and Jin Yin Hua.
  • Effective doses may include 2.5wt.%-5.0wt.% of said herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • Herbal formulations including a majority to an entirety of the three herbs Da Huang, Sheng Di Huang and Jin Yin Hua have demonstrated significant inhibitory effects on secretion of TNF-a, TARC and VEGF in keratinocytes (HaCaT), considerable downregulation of IL-6 in RAW264.7 cells and IgE in human myeloma cell line-U-266, as well as inhibition of JAK-l/JAK-3.
  • lotion, cream, gel, shampoo, foam, subdermal injections, IV, and oral formulations are provided herein.
  • Diagnostic test kits are provided in accordance with certain embodiments that include diagnosis-based treatments, diagnostic testing that involve novel markers or novel combinations of markers or novel reagents or combinations thereof.
  • An example of a diagnostic test kit in accordance with certain embodiments includes a test kit for measuring certain markers in patient bodily samples (e.g., serum or sera from skin washings, liquid blood serum, keritinocytes, or fibroblasts, or combinations thereof).
  • the example test kit may further include an indicator for communicating a diagnosis to the patient based on the results of the measuring and known correlations between levels of markers and predispositions with one or more diseases, conditions, ailments or disorders.
  • a shampoo, cream, lotion, pills, skin patches, gel, nanogel, injection pens, ointments, subdermal injections, IV bags, tablets, capsules, nano-lipid carriers, nano-chrystals, nano-particulates, subcutaneous implants, stents, or combinations thereof, may be provided with the test kit or may be advised based on the diagnosis, for administering treatment to the patient based on the diagnosis.
  • Such developed therapies may include one or more of Etanercept, Betamethotrexate, Methotrexate, 5-fluoroviacil, Paclitaxel, Adriamycin (doxorubicin), Etoposide, 5-fluorourasil, Docetaxil, Vincristine, Irinotecan, Methylprednisolone, Carboplatin, dacarbazine, Acitretin, Glycyrrhizin, Paeonia lactiflora, Glycyrrhiza uralensis, Mahonia aquafolium, Aloe vera, Indigo naturalis, Kaku nut oil, Camptotheca acuminatanut, Calcipotriol, tazarotene, Otezla, Embrel, Humira, Cinzia, Cosentyx, Remicade, Simponi, Taltz, Steroids, Tacrolimus, Prograf,
  • An herbal medicinal composition may be administered alone or in combination with an established treatment regimen such as any of those described herein before, during or after administration of the established regimen.
  • An example two herb combination in accordance with certain embodiments includes Da Huang and Sheng Di Huang. Another two herb combination includes Da Huang and Jin Yin Hua. Another two herb combination includes Sheng Di Huang and Jin Yin Hua. A three herb combination includes Da Huang, Sheng Di Huang and Jin Yin Hua.
  • Figure 4 illustrates the effect on live cells of five combinations of herbs each in two concentrations 1 :40 and 1 :80.
  • Cal includes a combination of all eighteen herbs
  • C2 includes a combination of Jin Yin Hua, Da Huang, Mu Dan Pi and Di Gu Pi
  • C3 includes a combination of Da Huang, Sheng Di Huang and Jin Yin Hua
  • C4 and C5 include combinations of the other eleven herbs (Zi Cao, Xuan Shen, Shi Gao, Bai Shao, Chi Shao, Hong Hua, Da Qing Ye, Qing Dai, Bai Zhu, Shi Wei and Rou Gui) of the eighteen herbs, i.e., not in combination with any of the seven herbs (Sheng Di Huang, Da Huang, Jin Yin Hua, Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi).
  • a treatment method in accordance with certain embodiments may include administering periodic doses of Pemetrexed, Pralatrexate, Methotrexate sodium, Pemetrexed Disodium or a folate analog metabolic inhibitor, alone or in combination with methotrexate, and/or another known treatment regimen described herein or as understood by those skilled in the art, along with an herbal combination of one or more of Da Huang, Sheng Di Huang, and Jin Yin Hua, and/or one or more of the other herbs described herein, for treating a patient with psoriasis, eczema, melanoma, inflammation or another inflammatory or autoimmune disease or form of cancer that is known to be effectively treated with methotrexate or another known treatment described herein or a discovered treatment such as for treating cancer of the breast, skin, bladder, head and neck, or lung, osteosarcoma, lymphoma, or trophoblastic neoplasms, or inflammation, or an autoimmune disease such as rheumatoid arthritis,
  • a very low dose example for a 100 kg patient includes 0.4 grams Da Huang, 0.4 grams Jin Yin Hua and 1.2 grams Sheng Di Huang.
  • a medium dose example includes 0.2 grams Da Huang, 0.2 grams Jin Yin Hua and 0.6 grams Sheng Di Huang.
  • a treatment regimen may include 1-10 gram daily doses of combinations of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • a treatment regimen may include 2-5 gram daily doses, or approximately 3 gram daily doses.
  • 1.5 gram doses may be administered twice daily, i.e., 1.5 grams twice a day.
  • a total daily dose may be administered in the form of four (4) tablets, e.g., 2 tablets, twice a day, of 1.0 gram each containing 750 mg of a combination of Da Huang, Sheng Di Huang and Jin Yin Hua as well as 250 mg of excipients.
  • a psoriasis treatment regimen may include administration of combinations of two or more of Da Huang, Sheng Di Huang and Jin Yin Hua along with an IL- 23/pl9 inhibitor.
  • an Alzheimer's or Parkinson's treatment regimen may include administration of combinations of two or more of Da Huang, Sheng Di Huang and Jin Yin Hua, alone, or along with another approved Alzheimer's or Parkinson's treatment.
  • Desatinib and/or another LYN, BTK and/or ABL inhibitor, and/or Fostamatinib and/or another SYK, FLT3, KIT, LCK, JAL1, JAK3, PLC, AKT and/or BCR inhibitor, and/or Idelalisib (GS-1101) or another P13K delta inhibitor, and/or Ibrutinib and/or another BTK inhibitor and/or Gefitinib and/or another Zap 70 inhibitor, and/or Dasatinib and/or another Lyn inhibitor, or another approved treatment for CLL and/or another leukemia or other cancer medication may be supplemented by administration of combinations of two or more of Da Huang, Sheng Di Huang and Jin Yin Hua.
  • a medicinal tablet composition for example for oral administration that may include one or more of the following further ingredients: 125 mg of MCC (Avicel), 20 mg of talc powder, 30 mg of aerosol 200, 10 mg of croscarmellose sodium and/or 30 mg of PVPK 30.
  • This example may also include one or more of the following lubrication ingredients: 20 mg of croscarmellose sodium, 5 mg of aerosol 200, 20 mg of talc powder and/or 10 mg of magnesium sterate.
  • a medicinal cream is also provided for topical administration that includes the above active herbal combination ingredient, in aqueous extract and in an example concentration of 2.5%, and one or more of the following further ingredients: till oil, cetostearyl alcohol, arlacel 165, light liquid paraffin, cresmer wax EW, stearyl stearate, butyl hydroxyl toluene, propylene glycol, sodium methyl paraben, sodium propyl paraben, glycerol, sandalwood oil.
  • a cream placebo may be formulated for clinical trials that substitutes F-24 chocolate brown color TAS and brilliant blue color for the above active herbal combination ingredient.
  • NSAIDs such as ibuprofen, naproxen and aspirin, other non-steroidal anti-inflammatories, acetaminophen, and/or steroidal anti -inflammatories may be combined with an herbal combination of one or more of Da Huang, Sheng Di Huang and Jin Yin Hua and/or one or more other herbs or molecules described herein, with or without administration of a known or discovered treatment, before, during or after the herbal treatment, to treat inflammation or other ailments that are commonly treatable with NSAIDs, including chronic pain.
  • Formulations may be prepared for oral or topical administration as long release, lipidized dosage compositions or as short release non-lipidized formulas.
  • a cooking process may be performed as in the example of Figures 5A-5B.
  • a step 502 in a cooking process may include taking about 25-30 grams of a first herb, e.g., da Huang, and a second herb, e.g., Jin Yin Hua, and grinding in a mixer grinder for three to five minutes or until a fine powder has been mixed and ground.
  • a step 504 in the process may include taking about 75-80 grams of a third herb, e.g., Sheng di Huang, and grinding in a mixer grinder for three to five minutes or until a fine powder has been mixed and ground.
  • a shampoo in accordance with certain embodiments includes one or more active herbs or herbal extracts or emotives that are described in several examples herein. These one or more active herbs or herbal extracts serve to promote treatment of certain hair and scalp conditions such as psoriasis, eczema, dermatitis, melanoma, hair loss and other hair or scalp conditions described herein or understood by those skilled in the art.
  • a preservative may be included in a shampoo in accordance with certain embodiments. The preservative may be configured to prevent microbial growth. Examples of preservatives that may be contained in a shampoo in accordance with certain embodiments include paraben free, formaldehyde donor free and halogenated free.
  • Figure 9 schematically illustrates certain targets of medicinal compositions including combinations of Da Huang, Sheng Di Huang and Jin Yin Hua (3HX), in accordance with certain embodiments.
  • Figure 9 illustrates a hyper proliferation of keratinocytes 902, e.g., as may be present in a patient suffering with an inflammatory skin condition, or melanoma, or an
  • a known or discovered treatment regimen is supplemented with a low dose formula including 3.3-20 grams of Jin Yin Hua and 10-60 grams of Sheng Di Huang.
  • a known or discovered treatment regimen is supplemented with a low dose formula including the one herb including 3.3-30 grams of Jin Yin Hua.
  • a known or discovered treatment regimen is supplemented with a low dose formula including the one herb including 10-90 grams of Sheng Di Huang.
  • a known or discovered treatment regimen is supplemented with a medium dose formula including the three herbs including 10-100 grams of Da Huang, 25-250 grams of Sheng Di Huang, and 10-100 grams of Jin Yin Hua.
  • a known or discovered treatment regimen is supplemented with a medium dose formula including 10-100 grams of Da Huang and 25-250 grams of Sheng Di Huang.
  • a known or discovered treatment regimen is supplemented with a medium dose formula including 10-100 grams of Jin Yin Hua and 25-250 grams of Sheng Di Huang.
  • a known or discovered treatment regimen is supplemented with a low dose herbal formula that includes 3.3-10 grams of Da Huang, and 13.3-40 grams of Sheng Di Huang in about 100-300 grams of water, or in dry or lipidized form for oral, topical, sub-dermal or IV administration.
  • a known or discovered treatment regimen is supplemented with a medium dose herbal formula that includes 15-100 grams of Da Huang and 45-300 grams of Sheng Di Huang in about 600-4000 grams of water, or in dry or lipidized form for oral, topical, sub- dermal or IV administration.
  • a known or discovered treatment regiment is supplemented with a low dose herbal formula that includes 0.25-25 grams of Sheng Di Huang in about 2.5-250 grams of water, or in dry or lipidized form for oral, topical, sub-dermal or IV administration.
  • a known or discovered treatment regimen is supplemented with a low dose herbal formula that includes 0.20-0.50 grams of Da Huang and 0.40-1.0 grams of Sheng Di Huang in about 6-50 grams of water, or in dry or lipidized form for oral, topical, sub-dermal or IV administration.
  • Surprise effectiveness is also provided by very low dose herbal combinations of Da Huang, Sheng Di Huang and Jin Yin Hua and by combinations of low doses of one or more of Da Huang, Sheng Di Huang and JinYin Hua with certain herbal extracts, molecules and/or known medicines. Examples includes
  • An example nanogel or nano-particulate lotion, cream, ointment or shampoo formulation may include carbopol ultraze 21/polymer surfactant. Triethanolomine may be advantageously used to convert lotion to gel and/or to neutralize a level of ph to between 5-8, 5.5-7.5 or 6-7 for topical application.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un kit médical pour le psoriasis, l'eczéma ou d'autres infections cutanées d'origine inflammatoire et/ou auto-immunes, ou le mélanome, BCC ou d'autres cancers, ou la leucémie, comprenant un écouvillon ou un autre outil de prélèvement d'échantillons de la peau, un essai cytokine multiplex pour mesurer les niveaux de plusieurs cytokines, comprenant l'IL-17, l'IL-23 et le TNF-alpha, un indicateur d'un résultat de test de diagnostic, et un shampoing, une lotion, un onguent sous forme de crème ou un nanogel ou une autre formulation médicinale topique qui comprend une composition de dosage comprenant des doses de 20 à 160 mg/kg d'une combinaison de plantes de Sheng Di Huang, Da Huang et Jin Yin présentant une taille moyenne de particule qui est inférieure à 450 nm.
PCT/US2017/039177 2016-06-29 2017-06-26 Procédés de prognostic et de diagnostic de phytothérapie permettant de traiter les dermatoses, les maladies auto-immunes et les troubles inflammatoires WO2018005308A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/197,740 2016-06-29
US15/197,745 US20170000837A1 (en) 2013-05-22 2016-06-29 Prognostic and Diagnostic Kits and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
US15/197,740 US20170000836A1 (en) 2013-05-22 2016-06-29 Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
US15/197,745 2016-06-29

Publications (1)

Publication Number Publication Date
WO2018005308A1 true WO2018005308A1 (fr) 2018-01-04

Family

ID=59895356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039177 WO2018005308A1 (fr) 2016-06-29 2017-06-26 Procédés de prognostic et de diagnostic de phytothérapie permettant de traiter les dermatoses, les maladies auto-immunes et les troubles inflammatoires

Country Status (1)

Country Link
WO (1) WO2018005308A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1539404A (zh) * 2003-10-29 2004-10-27 天津郁美净集团有限公司 含有黄腐酸的洁肤组合物
WO2014047292A2 (fr) * 2012-09-20 2014-03-27 Bpw Sciences, Lp Compositions de polyélectrolytes bioactifs à partir de matières organiques humidifiées et utilisations associées
WO2015082950A1 (fr) * 2013-12-02 2015-06-11 Sirbal Ltd. Combinaisons de plantes pour le traitement d'une affection cutanée
US9095606B1 (en) * 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US20160051553A1 (en) * 2012-01-31 2016-02-25 Sirbal, Ltd. Molecular and Herbal Combinations with Methotrexate for Treating Diseases and Inflammatory Ailments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1539404A (zh) * 2003-10-29 2004-10-27 天津郁美净集团有限公司 含有黄腐酸的洁肤组合物
US9095606B1 (en) * 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US20160051553A1 (en) * 2012-01-31 2016-02-25 Sirbal, Ltd. Molecular and Herbal Combinations with Methotrexate for Treating Diseases and Inflammatory Ailments
WO2014047292A2 (fr) * 2012-09-20 2014-03-27 Bpw Sciences, Lp Compositions de polyélectrolytes bioactifs à partir de matières organiques humidifiées et utilisations associées
WO2015082950A1 (fr) * 2013-12-02 2015-06-11 Sirbal Ltd. Combinaisons de plantes pour le traitement d'une affection cutanée

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIORADIATIONS STAFF: "New Multiplex Assays for Th17 Cytokine Research | Bioradiations", 6 March 2012 (2012-03-06), XP055416339, Retrieved from the Internet <URL:http://www.bioradiations.com/new-multiplex-assays-for-th17-cytokine-research/> [retrieved on 20171017] *
JUSTIN GANDY ET AL: "Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema", CLINICAL. COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 8 September 2011 (2011-09-08), United Kingdom, pages 145, XP055415697, ISSN: 1178-7015, DOI: 10.2147/CCID.S23110 *
L. M. JOHNSON-HUANG ET AL: "Putting together the psoriasis puzzle: an update on developing targeted therapies", DISEASE MODELS & MECHANISMS, vol. 5, no. 4, 21 June 2012 (2012-06-21), pages 423 - 433, XP055033403, ISSN: 1754-8403, DOI: 10.1242/dmm.009092 *
MICHELLE A. LOWES ET AL: "Pathogenesis and therapy of psoriasis", NATURE, vol. 445, no. 7130, 22 February 2007 (2007-02-22), pages 866 - 873, XP055112765, ISSN: 0028-0836, DOI: 10.1038/nature05663 *
UWE WOLLINA: "Peat: A Natural Source for Dermatocosmetics and Dermatotherapeutics", JOURNAL OF CUTANEOUS AND AESTHETIC SURGERY, vol. 2, no. 1, 1 July 2009 (2009-07-01), pages 17 - 20, XP055415197 *

Similar Documents

Publication Publication Date Title
Rahman et al. Classical to current approach for treatment of psoriasis: a review
US20170000836A1 (en) Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
May et al. Oral herbal medicines for psoriasis: a review of clinical studies
EP2489358B1 (fr) Produit extrait d&#39;huile d&#39;indigo naturel et procédé de préparation et utilisation associée
JP3803398B2 (ja) 人体過剰対応抑制剤
KR20220123176A (ko) 피부 질환을 치료하기 위한 조성물
CN103784933B (zh) 复发性口腔溃疡散
CN105395577A (zh) 一种降尿酸组合物及其制剂
CN104784270A (zh) 一种消肿止痛外用制剂及其制备方法
US20170000837A1 (en) Prognostic and Diagnostic Kits and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer
CN101167937A (zh) 一种治疗风湿或类风湿的中药组合物贴膏及其制备方法
US11344598B2 (en) Herbal nanoformulations for treating psoriasis and other skin conditions
WO2018005308A1 (fr) Procédés de prognostic et de diagnostic de phytothérapie permettant de traiter les dermatoses, les maladies auto-immunes et les troubles inflammatoires
CN110025705A (zh) 一种治疗特应性皮炎的中药组合物及其制备方法和应用
AU2003255854A1 (en) Use of fermented wheat germ extract as anti-inflammatory agent
US20220105107A1 (en) Bioidentical progesterone cream infused with nanoemulsified cbd
CN102166282B (zh) 一种抗过敏或脱敏的药物组合物
Shingadiya et al. Ayurvedic Management of chronic Vitiligo (Shvitra): A case study
WO2016065674A1 (fr) Utilisation d&#39;ibrutinib pour une leucémie aiguë avec mutation flt3-itd
CN105362382A (zh) 一种治疗复发性口腔溃疡中药组合物及其应用
JP2010155813A (ja) アトピー性皮膚炎治療剤
CN110585208A (zh) 莲心碱作为5-脂氧合酶抑制剂的应用
CN109288907A (zh) 一种延丹胶囊及其制备方法与检测方法及新用途
Deo et al. Acute and sub‑chronic toxicity study of Brahmi ghrita in rodents
CN104274540B (zh) 含有雷公藤的中药组合物、其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17768535

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17768535

Country of ref document: EP

Kind code of ref document: A1